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An exploratory study of systemic administration of the toll-like
receptor-7 agonist 852A in patients with refractory metastatic
melanoma
Abstract
PURPOSE: A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic
neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, in
patients with metastatic melanoma. EXPERIMENTAL DESIGN: We undertook a phase II, multicenter,
open-label study in patients with chemotherapy-refractory metastatic melanoma. Patients received i.v.
852A, starting at 0.6 mg/m(2) and increasing to 0.9 mg/m(2) based on tolerance, thrice per week for 12
weeks. Clinical response was determined by Response Evaluation Criteria in Solid Tumors. Immune
effects of 852A were monitored by measuring serum type I IFN and IP-10 together with assessment of
immune cell markers in peripheral blood. RESULTS: Twenty-one patients were enrolled. Thirteen
patients completed the initial 12-week treatment cycle, with two discontinuing for adverse events
considered to be possibly related to study drug. Four (19%) patients had disease stabilization for >100
days. One patient had a partial remission after two treatment cycles, but progressed during the third.
Dose-limiting toxicity was observed in two patients. Serum type I IFN and IP-10 increased in most
patients on 852A administration. Serum type I IFN increases were greater after dosing with 852A 0.9
mg/m(2) than after 0.6 mg/m(2) (P = 0.009). The maximal increase in IP-10 compared with baseline
correlated with the maximal increase in type I IFN (P = 0.003). In the eight patients with immune cell
marker data, CD86 expression on monocytes increased significantly post-first dose (P = 0.007).
CONCLUSION: Intravenous 852A was well tolerated and induced systemic immune activation that
eventually resulted in prolonged disease stabilization in some patients with stage IV metastatic
melanoma who had failed chemotherapy.
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Abstract Purpose: A topicalToll-like receptor 7 (TLR7) agonist induces regression of cutaneous melano-
cytic neoplasms.We explored antitumor activity of a systemically administered TLR7 agonist,
852A, in patients with metastatic melanoma.
Experimental Design:We undertook a phase II, multicenter, open-label study in patients with
chemotherapy-refractorymetastaticmelanoma. Patients received i.v. 852A, starting at 0.6mg/m2
and increasing to 0.9 mg/m2 based on tolerance, thrice per week for 12 weeks. Clinical response
was determined by Response Evaluation Criteria in Solid Tumors. Immune effects of 852Awere
monitored by measuring serum type I IFN and IP-10 together with assessment of immune cell
markers in peripheral blood.
Results: Twenty-one patients were enrolled. Thirteen patients completed the initial 12-week
treatment cycle, with two discontinuing for adverse events considered to be possibly related to
study drug. Four (19%) patients had disease stabilization for >100 days. One patient had a partial
remission after two treatment cycles, but progressed during the third. Dose-limiting toxicity was
observed in two patients. Serum type I IFN and IP-10 increased inmost patients on 852A admin-
istration. Serum type I IFN increases were greater after dosing with 852A 0.9 mg/m2 than after
0.6mg/m2 (P =0.009).Themaximal increase in IP-10 comparedwithbaseline correlatedwith the
maximal increase in type I IFN (P = 0.003). In the eight patients with immune cell marker data,
CD86 expression onmonocytes increased significantly post-first dose (P = 0.007).
Conclusion: Intravenous 852Awas well tolerated and induced systemic immune activation that
eventually resulted in prolonged disease stabilization in some patients with stage IV metastatic
melanomawho had failed chemotherapy.
Melanoma is among the more immunogenic malignancies,
and as such, multiple immunotherapeutic treatments have
been investigated including IFN-a, interleukin-2, tumor necro-
sis factor a, adoptive cell transfer, and therapeutic vaccines
(1, 2). Overall response rates of 8% to 20% have been reported
with IFN-a or interleukin-2 monotherapy in advanced mela-
noma patients, but overall survival improvement has not been
shown (3). In the adjuvant setting, IFN-a is the only drug
significantly affecting relapse-free and overall survival (4).
Despite preexisting circulating T cells recognizing tumor
antigens in some patients and the ability to expand tumor-
reactive CTLs with tumor antigen immunization, effective
immunotherapy for melanoma remains elusive (5).
Toll-like receptors (TLR) recognize conserved pathogen-
associated molecular patterns (6). Manipulation of the innate
immune response through TLR activation may act as a bridge
toward enhancement of tumor-specific acquired immunity (7).
The small-molecule TLR7 agonist imiquimod induces IFN-a
production from plasmacytoid dendritic cells, as well as
proinflammatory cytokines from other cells (8). Imiquimod
has induced regression in melanoma lesions after topical
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administration (9–11). 852A {N-[4-(4-amino-2-ethyl-1H-imi-
dazo[4,5-c]quinolin-1-yl) butyl]methanesulfonamide, 3M-
001} is an analogue severalfold more potent and more selective
for TLR7 versus TLR8 activation than imiquimod in a human
HEK293 TLR-nuclear factor nB-luciferase cotransfection assay
(12). 852A is also more potent in inducing IFN-a production
by human peripheral blood mononuclear cells with a median
minimum concentration to produce >3-fold increase in
cytokines over control of 0.04 Amol/L for 852A versus
1.11 Amol/L for imiquimod (data on file, 3M Pharmaceuticals).
852A activates antigen-presenting cells, up-regulates costimu-
latory molecule expression, stimulates natural killer cell
activity, induces production of IFN-a by plasmacytoid dendritic
cells, and promotes plasmacytoid dendritic cell survival
(12, 13). Supernatant from 852A-treated human peripheral
blood mononuclear cells inhibited Hs294T and A375 melano-
ma cell proliferation in vitro; the effect was abrogated by
plasmacytoid dendritic cell depletion and partially neutralized
by preincubation of supernatant with anti–IFN receptor a/h
or anti– IFN-a.8 Although less active in rodents than in
humans, 852A delayed the onset of lung colonies in the
B16-F10 murine melanoma model.8 In a phase I dose-finding
study in 25 patients with refractory solid organ tumors, i.v.
administration of 852A thrice per week was associated with
cytokine induction at 0.6 mg/m2 whereas 1.2 mg/m2 was the
maximum tolerated dose (12).
To further explore the antitumor activity, immunologic
effects, and safety of 852A, we conducted an open-label study
of i.v. administered 852A in patients with metastatic melanoma
who relapsed after chemotherapy.
Patients andMethods
Patients. Patients were recruited at six centers (University Hospital,
Zu¨rich, Switzerland; Hoˆpital Ste Marguerite, Marseille, France; Hospital
Hotel Dieu, Lyon, France; University Clinic Schleswig-Holstein, Kiel,
Germany; University Clinic and Health Center for Skin Diseases,
Wu¨rzburg, Germany; and Skin Cancer Unit, Mannheim, Germany) in
accordance with Good Clinical Practice guidelines and the ethical
standards enunciated in the Declaration of Helsinki. The protocol and
amendments were reviewed and approved by independent ethics
committees and the medicines regulatory agency for each participating
country. Each patient gave written informed consent. The study was
registered at ClinicalTrials.gov (NCT0018933).
Male or female patients z18 years of age were eligible for
enrollment if they had advanced melanoma not responding to first
line of chemotherapy; measurable disease by Response Evaluation
Criteria in Solid Tumors with cutaneous or s.c. target lesions
>10 mm in diameter; Eastern Cooperative Oncology Group
performance status V2; a life expectancy z6 months; WBC count
z3.0  109 cells/L; absolute neutrophil count z1.5  109 cells/L;
platelet count z100  109/L; hemoglobin >100 g/L; alanine
aminotransferase and aspartate aminotransferase V2.5  upper limits
of normal; normal total bilirubin; and serum creatinine >1.8 mg/dL
or calculated creatinine clearance z60 mL/min (14, 15). Patients
were excluded if they had immunotherapy for melanoma 6 weeks
before first 852A dose (to decrease possible confounding by carry-
over immunologic effects); melanoma progression on IFN with/
without monochemotherapy (to increase the likelihood of seeing a
response in tumors sensitive to IFN-a because 852A mediate its
effects mainly through induction of endogenous IFN-a); pregnancy/
breast-feeding, significant malignancy, significant cardiac disease
including prolonged QT interval, coagulation disorder, active
infection or fever, and uncontrolled medical conditions. In addition,
patients were excluded if they had therapy within the 4 weeks or
required therapy with investigational agents, systemic or high-dose
inhaled or topical corticosteroids, immunosuppressive therapy, drugs
associated with QT prolongation and/or torsades de pointes, or
radiotherapy. Adequate contraception was required if applicable.
Treatment. 852A (3M Pharmaceuticals) as a sterile 0.2% solution
was administered by i.v. bolus at the clinic. Dosing was initiated at 0.6
mg/m2 of 852A thrice per week. Patients tolerating >4 weeks of
treatment could escalate to 0.9 mg/m2 thrice per week; patients not
tolerating treatment could de-escalate to 0.6 mg/m2 twice per week. The
treatment duration was 12 weeks or until disease progression
(treatment cycle 1); patients with at least stable disease were allowed
to receive additional 12-week treatment cycles.
Clinical assessments. Tumor burden was assessed at pre-study, at
the end of each treatment cycle, and at the end of study by physical
examination and imaging. Adverse event and concomitant medication
information was collected at each visit. Physical examination, vital
sign measurements, routine clinical laboratory tests, 12-lead electro-
cardiograms, and Eastern Cooperative Oncology Group status
determination were obtained at pre-study, at least weekly during
treatment cycle 1, every 2 weeks during additional treatment cycles,
and at the end of study. Thyroid-stimulating hormone was measured
at pre-study, every 4 weeks during treatment, and at the end of study.
Transthoracic echocardiograms, added after the start of the study, were
done at pre-study, at the end of each treatment cycle, and at the end
of study. Clinical response was determined by Response Evaluation
Criteria in Solid Tumors based on tumor evaluation done at baseline
and on completion of the treatment at week 13 or earlier using
physical examination of palpable lesions and imaging [computed
tomography (CT), positron emission tomography (PET), and/or
magnetic resonance imaging scans]. Study conduct and source data
were monitored by sponsor personnel for accuracy. Clinical labora-
tories were accredited. A single cardiologist interpreted all electro-
cardiograms. Data were double data entered with verification. All
queries were resolved and subject evaluability was determined before
database lock.
Immune monitoring. Immunologic monitoring included serum
cytokine measurement from blood obtained at pre-dose and 6 and
24 h post-dose for dose 1 of weeks 1, 6, and 12. Type I IFN was
measured by a bioassay with a lower limit of quantitation of 1 IU/mL
(16). IP-10 was measured by an enzyme-linked immunoassay (R&D
Systems) with a lower limit of quantitation of 40 pg/mL.
For patients enrolled at the Zurich study center, blood was taken at
pre-dose and 24 h post-dose for dose 1 of weeks 1, 6, and 12 to assess
activation markers on monocytes (CD80 and CD86) and plasmacytoid
dendritic cells (CD80, CD86, and CCR7), as well to measure peripheral
plasmacytoid dendritic cell and myeloid dendritic cell frequency by
fluorescence-activated cell sorting. In addition, pre-dose plasmacytoid
dendritic cell and myeloid dendritic cell frequency was measured for
dose 1 of weeks 2 and 4. Within 60 min after blood draw, antibodies
were added to a test tube as recommended by the manufacturer
(antibodies and control isotypes listed in Supplementary Table S1)
followed by addition of 100 AL of whole blood. After incubation with
OptiLyze No-Wash lysing solution (Beckman Coulter Intl.), erythro-
cytes were lysed and stained cell populations fixed. For activation
marker expression, plasmacytoid dendritic cells and monocytes were
gated from whole blood peripheral blood mononuclear cells using
forward scatter/side scatter followed by gating on CD123high/lin 1low
and CD123high/HLA-DR+ (for plasmacytoid dendritic cells) and by
gating on CD14+CD19- (for monocytes). Mean fluorescence intensity
8 J.R. Inglefield, C.D. Dumitru, S.S. Alkan, S.J. Gibson, K.E. Lipson, M.A.Tomai, C.J.
Larson, J.P.Vasilakos. TLR7 agonist 852A inhibition of tumor cell proliferation is
dependent on plasmacytoid dendritic cells and type I IFN, submitted.
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was determined for each parameter for the selected population. The
frequencies of CD123high/HLA-DR+/lin 1- (for plasmacytoid dendritic
cells) and CD11c+/HLA-DR+/lin 1- (for myeloid dendritic cells) in
peripheral blood mononuclear cells were used to determine the
frequencies of the respective dendritic cell populations in peripheral
blood.
Statistical powering. This was a two-stage open-label study using a
Simon’s minimax design (17). The null hypothesis (H0) assumed a true
response rate V10% versus z30% for the alternative hypothesis. In
stage I, for 15 to 18 evaluable patients, >2 patients with a partial
response or complete response were required to proceed to stage II.
With a total enrollment of 19 to 28 evaluable patients, there was 80%
(b = 0.20) power to detect a response rate z30% (a = 0.05). With this
design, the average expected H0 sample size was 19.6 with an average
probability of early study stoppage of 0.38.
Data analysis. The primary end point was overall patient tumor
status by Response Evaluation Criteria in Solid Tumors. The sum of
the longest diameter for all target lesions for a patient was calculated
and used as the reference. All patients who received >1 dose were
included in the safety assessment; adverse events were coded using the
Medical Dictionary for Regulatory Activities. Descriptive clinical
analyses were done using SAS version 9 (SAS Institute, Inc.). Group
changes in serum type I IFN, IP-10, and cell activation markers were
summarized over time. Natural log-transformed type I IFN and IP-10
values were used to calculate the maximal observed positive change.
Statistical analyses were done using SPSS version 12 (SPSS) and Excel
2003 (Microsoft Corp.).
Results
Patients
The first subject was enrolled on 19 May 2005 and the last
subject completed the study on 12 October 2006. The analysis
Table 1. Baseline patient characteristics and response during study
Patient Age (y);
sex; race
Primary tumor type;
AJCC stage (ECOG score)
Target tumors (n);
LD sum (cm)
Nontarget
involvement
Prior
therapy
11-61 62; female; White Unknown; IV M1a (1) 1; 2.6 Not applicable Dacarbazine, peg-IFNa,
thalidomide
11-62 43; female; White Nodular; IV M1a (2) 4; 25 Not applicable Dacarbazine, carbaplatin,
vinblastin, radiation
11-63 64; male; White Unknown; IV M1c (1) 4; 20.7 Lymph node, bone,
pleura, mesentary
Temozolomide
11-64 31; female; White Nodular; IV M1b (0) 1; 3.5 Lung, skin Adeno-IL-2, dacarbazine,
thalidomide
11-65 52; female; White Unknown; IV M1c (0) 2; 9.9 Kidney, bladder Adeno-IL-2, thalidomide,
dacarbazine
11-66 73; male; White Nodular; IV M1b (0) 1; 3.8 Lung Dacarbazine, IFNa
11-67 62; male; White Acral lentiginous;
IV M1c (0)
7; 32 Lymph node, adrenal,
kidney, spleen, pancreas
Dacarbazine
11-68 44; male; White Superficial spreading;
IV M1b (0)
1; 2.1 Lymph node, lung, kidney Dacarbazine, cisplatin,
carmustin, radiation
21-01 77; female; White Nodular; IV M1c (1) 2; 6.4 Lung Peg-IFNa, dacarbazine,
radiation
21-03 54; male; White Unclassified; IV M1c (1) 4; 20.7 Lymph node, lung, liver,
skin, pancreas, spleen
Dacarbazine
31-37 56; female; White Unknown; IV M1a (0) 5; 8.5 Lymph node IFNa, dacarbazine
31-38 63; male; White Acral lentiginous;
IV M1c (0)
4; 12.8 Lymph node, lung Dacarbazine, fotemustine
31-39 69; male; White Nodular; IV M1c (1) 3; 6.3 Lung IFNa, dacarbazine
31-40 77; male; White Superficial spreading;
IV M1c (1)
2; 6.3 Lymph node, lung, skin IFNa, dacarbazine,
fotemustine, radiation
32-43 29; male; White Unclassified; IV M1c (0) 1; 5.2 Bone, skin Dacarbazine
32-44 76; male; White Unknown; IV M1b (0) 5; 20.7 Lymph node, lung, liver Dacarbazine
32-45 64; male; White Unclassified; IV M1c (0) 1; 3.2 Lymph node, lung,
liver, skin
Imatinib, survivin in
montanide, fotemustine
32-46 60; male; White Unclassified; IV M1c (0) 1; 2.6 Lung, liver Fotemustine, imatinib
32-47 68; male; White Lentigo maligna; IV M1a (0) 1; 2.1 Lymph node, lung Dacarbazine
33-49 48; female; White Superficial spreading;
IV M1c (1)
2; 7.8 Lymph node, lung, liver, skin Peg-IFNa, dacarbazine
33-50 72; male; White Unknown; IV M1b (1) 1; 2.5 Lymph node, thoracic Treosulfan, gemcitabine,
dacarbazine
Abbreviations: AJCC, American Joint Commission on Cancer; ECOG, Eastern cooperative oncology group; LD, longest diameter; DC,
discontinued; C, cycle; W, week; EOS, end of study; SD, stable disease; PR, partial response; PD, progressive disease; IL-2, interleukin 2; AE,
adverse event.
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database was finalized on 05 January 2007. Of 31 patients
screened, 21 were enrolled into stage I; there were no
enrollments for stage II (for explanation see below). The
patients were all White, mostly male (62%), and had a mean
age of 59 F 14 years (Table 1). Nineteen percent of patients
were American Joint Committee on Cancer stage IV M1a, 24%
IV M1b, and 57% IV M1c. Most patients had 1 (43%), 2 (19%),
or 4 (19%) target lesions (range, 1-7). Mean sum longest
diameter was 9.7 F 8.7 cm (range, 2.1-31). Lung (67%) and
lymph nodes (57%) were the most common nontarget sites.
Thirteen patients completed treatment cycle 1; five withdrew for
adverse events and three for lack of therapeutic effect. Three
patients had one additional treatment cycle and a fourth had
two additional cycles.
Tumor response
During the study, 71% (15 of 21) of patients progressed,
19% (4 of 21) had disease stabilization, and 10% (2 of 21)
were not evaluable (Table 1). Patient 61, who had two
additional treatment cycles, had a partial response after the
second cycle (Fig. 1), but progressed after the third cycle. Four
patients had stable disease for >100 days (275, 197, >105, and
>185 days, where ‘‘>’’ indicates stable disease at last study
visit).
Safety
Mean cumulative treatment cycle 1 exposure was 19.28 F
8.53 mg/m2 (1.80-28.28). During the study no patient died.
Nine (43%) patients had 17 serious adverse events, of which
11 (2 adverse events of nausea and 1 each of vomiting,
fatigue, chills, pyrexia, dizziness, muscle weakness, muscle
tightness, pain in extremity, and anemia) were considered
possibly/probably related to study drug. Five (24%) patients
discontinued for adverse events, of which two had adverse
events (grade 3 fatigue and grade 2 dizziness and nausea)
considered possibly related to study drug. Two (10%) patients
experienced dose-limiting toxicities such as grade 3 thrombo-
cytopenia and grade 3 cholestasis. Eight (38%) patients had at
least one adverse event of maximal intensity of severe, whereas
12 (57%) had adverse events of maximal intensity of
Table 1. Baseline patient characteristics and response during study (Cont’d)
Cycle 1 treatment status; received 0.9 mg/m2 Clinical response
Target Nontarget Overall
Completed; yes Cycle 1 SD IR SD
Cycle 2 PR NA PR
Cycle 3 PD IR PD
EOS PD IR PD
DC C1W1 for AE (fatigue); no NA NA NA NA
DC C1W6 for progression; no NA NA NA NA
Completed; yes Cycle 1 SD PD PD
Completed; yes Cycle 1 PD PD PD
Completed; yes Cycle 1 SD IR SD
Cycle 2 SD IR SD
Completed; yes Cycle 1 SD PD PD
DC C1W4 for AE (pelvic vein thrombosis); no Cycle 1 PD PD PD
Completed; yes Cycle 1 PD PD PD
DC C1W2 for AE (necrosis hepatic metastasis); no Cycle 1 NA PD PD
Completed; no Cycle 1 SD IR SD
Cycle PD PD PD
EOS PD PD PD
Completed; yes Cycle 1 PD PD PD
DC C1W11 for AE (pleural effusion); no Cycle 1 PD PD PD
DC C1W8 for AE (nausea and dizziness); no Cycle 1 SD PD PD
DC C1W8 for progression; yes Cycle 1 PD PD PD
Completed; yes Cycle 1 PD PD PD
Completed; yes Cycle 1 PD IR PD
EOS PD PD PD
Completed; no Cycle 1 PD IR PD
Completed; no Cycle 1 PD IR PD
DC C1W7 for progression; yes Cycle 1 PD PD PD
Completed; yes Cycle 1 SD IR SD
SystemicTLR7 Agonist forMetastaticMelanoma
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moderate. The adverse events reported by the most patients by
preferred terms were pyrexia (67%), fatigue (62%), nausea
(52%), chills (48%), myalgia (29%), pain in extremity (29%),
and headache (29%), most of which are reminiscent of ‘‘flu-
like’’ syndrome described after treatment with other TLR7
agonists and IFN-a (refs. 12, 18–20; Table 2). No inflamma-
tory reaction of tumor lesions in the skin possibly or probably
related to study drug was observed. Severe adverse events
reported by >10% of patients were anemia, nausea, and pain.
For laboratory tests, there was tendency toward a decrease in
hemoglobin, hematocrit, RBC count, and serum phosphorus
(data not shown); three patients had adverse events of anemia
Fig.1. Clinical response to852A inpatient61visualizedbyPET-CT.BaselinePET-CTevaluationof the infracarinal lymphnodemetastasis [A ; fusedaxialPET-CTimage showing
pathologically increased [18F]fluorodeoxyglucose (FDG) uptake of the metastasis in bottom left corner]. PET-CTevaluation after two treatment cycles shows decrease both
in size and in fluorodeoxyglucose activity of the infracarinal lymph node metastasis (B ; fused axial PET-CT image in bottom left corner).
Table 2. Adverse events reported by z10% of patients (preferred term)
System organ class Preferred term n (%); total patients = 21
Blood and lymphatic system disorders Anemia 3 (14)
Gastrointestinal disorders Abdominal pain 4 (19)
Abdominal pain upper 5 (24)
Constipation 3 (14)
Diarrhea 3 (14)
Nausea 11 (52)
Vomiting 5 (24)
General disorders and administration site conditions Chills 10 (48)
Fatigue 13 (62)
Malaise 3 (14)
Pain 3 (14)
Pyrexia 14 (67)
Infections and infestations Nasopharyngitis 3 (14)
Metabolism and nutrition disorders Anorexia 5 (24)
Musculoskeletal and connective tissue disorders Arthralgia 3 (14)
Myalgia 6 (29)
Pain in extremity 6 (29)
Shoulder pain 4 (19)
Nervous system disorders Dizziness 3 (14)
Headache 6 (29)
Psychiatric disorders Insomnia 5 (24)
Sleep disorder 3 (14)
Respiratory, thoracic, and mediastinal Cough 4 (19)
CancerTherapy: Preclinical
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(Table 2). No clinically meaningful qualitative changes in
electrocardiogram measurements were noted and none of the
quantitative changes were considered related to 852A. The
distribution of absolute Bazett QTc (in milliseconds) was
comparable when patients were dosed at 0.6 or 0.9 mg/m2.
The majority in both groups had a Bazett QTc between 391
and 420 ms; one patient had an increase of >60 ms on one
occasion. One patient had an echocardiogram consistent with
a cardiomyopathy; no baseline study evaluation was available
but similar abnormalities were noted on echocardiography
before the study.
Immunologic markers
Serum cytokines. Thirteen patients had cytokine data
through week 12 and five patients through week 6 of treatment
cycle 1. Serum type I IFN increased post-dose for week 1 (P =
0.025; Fig. 2A) and for IP-10 for weeks 1 and 6 (P = 0.035 and
0.001, respectively; Fig. 2B). Increases were greater at 6 h than
at 24 h for both parameters. In the 13 patients who dosed at
0.9 mg/m2 thrice per week and had cytokine measurements,
the maximal increase for type I IFN post-dose was greater after
the 0.9 mg/m2 dose than the 0.6 mg/m2 dose (mean, 3.24 F
2.32 versus 1.04 F 1.06; P = 0.009, paired t test). IP-10 levels
similarly increased but not significantly (mean, 1.67 F 1.27
versus 0.99 F 0.91; P = 0.110). For the four patients who
remained at 0.6 mg/m2 and had cytokine data after the initial
dose, the mean maximal increases for type I IFN and IP-10
were 1.45 F 1.66 and 0.92 F 0.65 after the first dose versus
1.86 F 2.17 and 0.46 F 0.33, respectively, after a subsequent
0.6 mg/m2 dose. The maximal increase in IP-10 compared
with baseline seemed to correlate with the maximal increase in
type I IFN (Pearson’s correlation coefficient r = 0.705, P =
0.003). No differences were observed in the maximal cytokine
increase between patients who had progressive disease
throughout the study (n = 15) versus those who were stable
disease or partial response for at least one treatment cycle (n =
4; data not shown).
Cellular markers. Eight patients had adequate data on
markers of cell activation. There was an increase in monocyte
CD86 expression 24 h post-dose at week 1 (P = 0.007, paired t
test) that persisted to a lesser extent at weeks 6 and 12 (P =
0.108 and P = 0.064, respectively; Fig. 3). In weeks 1 and 6,
serum IFN-a increases correlated with CD86 expression on
monocytes measured at 24 h post-dose (Pearson’s correlation
coefficient r = 0.734, P = 0.038 and r = 0.840, P = 0.036,
respectively). No consistent pattern was observed for monocyte
CD80 expression or CD80, CD86, and CCR7 expression on
plasmacytoid dendritic cells. During treatment cycle 1, most
patients had decreases in pre-dose peripheral plasmacytoid
dendritic cell (six of seven) and myeloid dendritic cell
frequency (five of seven; Fig. 4A and B, respectively).
Irrespective of the changes in plasmacytoid dendritic cell
frequency, over the treatment duration, individual patients
Fig. 2. Change in serum type I IFN (A) and IP-10 (B). Grouped by treatment week
displaying median (bar), quartile range (box), minimum/maximum (whiskers),
outliers (circles ; values1.5-3 box lengths from ends), and extremes (asterisks ;
values >3 box lengths from ends). Significant changes across time points for a
week (ANOVA) and between time points (Tukey’s multiple comparison test) are
indicated.
Fig. 3. Change in CD86 expression on peripheral blood monocytes from
pre-dose (0 h) to post-dose (24 h) in week1. Columns, CD86 mean fluorescent
intensity. Significant changes (paired t test) are indicated.
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tended toward increased pre-dose expression of CD80, CD86,
and CCR7 on plasmacytoid dendritic cells (data not shown).
No such changes were evident for monocytes.
Discussion
In this study of systemic 852A administration in patients
with advanced melanoma refractory to first-line chemotherapy,
although no patient achieved a complete response, one
experienced a nonsustained partial response and four had
overall stable disease lasting z100 days. The limited efficacy
observed with 852A monotherapy was not necessarily surpris-
ing, given the advanced disease of the enrolled population.
The observed adverse events attributable to study drug were
consistent with those previously observed with systemic admin-
istration of 852A, imiquimod, resiquimod, as well as with
exogenous recombinant IFN-a, and seemed to reflect cytokine-
mediated effects rather than direct toxicity (12, 18–20). The
dose levels selected for evaluation in this study were
lower than the 1.2 mg/m2 dose considered to be the maximum
tolerated dose in a phase I study (12). Although f1/3 of
patients had adverse events of severe intensity, and dose-
limiting toxicities occurred at 0.6 and 0.9 mg/m2, the overall
safety profile was deemed tolerable, given the underlying
disease. Although limited by the patient number and historical
comparison, the gastrointestinal adverse events observed in this
study seemed to be less frequent and/or less severe than
observed in clinical studies of oral administration of imiquimod
or resiquimod (19, 20). The intestinal tract contains a large
number of immune cells, including dendritic cells, and TLR7
expression has been reported on hepatocytes (21, 22). Oral
administration may result in high localized cytokine induction,
affecting gastrointestinal tolerance, but may also spill over into
the systemic circulation despite low serum drug levels.
Prolongation of action potential duration in hERG potassium
ion channels has been observed in vitro at 3,000 ng/mL of 852A,
along with QTc increases in dogs at 2.5 mg/kg (data on file,
3M Pharmaceuticals). However, no trends in electrocardiogram
QTc measurements of concern were observed in this study. In
addition, mean serum 852A concentrations at 5 min post-
infusion ranged from 10 to 100 ng/mL after doses of 0.15 to
2.0 mg/m2 in the phase I study, well below the concentration
where in vitro effects were observed (12).
By activating TLR7 on plasmacytoid dendritic cells, 852A was
shown to induce IFN-a production in vitro as well as in vivo
(12). Similar to other TLR7 agonists, 852A also enhances
production of IP-10 (CXCL10), which is in turn inducible by
IFN-a and dependent on IFN-a receptor (12, 23, 24). In
addition, IP-10 has been shown to promote the induction of
T helper 1 cytokines (e.g., IFN-g; refs. 25, 26), which are
necessary for an efficient antitumor response (27). IP-10
represents therefore a downstream marker of presence of
IFN-a as well as an indicator of T helper 1 responses. 852A
pharmacologic activity was thus evidenced by increases in
serum type I IFN and IP-10 in the majority of patients.
Inducibility of IP-10 by IFN-a was supported by the correlation
between the two. Preclinical studies suggest that 852A can also
activate monocytes, likely through IFN-a because monocytes
do not express TLR7 (28). Expression of monocyte activation
markers in most of the patients (that had cell marker analyses
done) was increased on treatment with 852A and correlated
with type I IFN activity, confirming this observation. Disap-
pointingly, changes in expression of activation markers as well
as frequency of other immune cell populations in peripheral
blood that were analyzed in this study (plasmacytoid dendritic
cells, myeloid dendritic cells, and monocytes; data for B cells
not shown) failed to reveal any pattern of association with the
study drug.
There was tendency for the maximal increase in serum type I
IFN to be greater after the 0.9 mg/m2 dose as compared with
after the initial or a subsequent 0.6 mg/m2. This may due to
increased 852A dose as well as to repeated dosing; augmenta-
tion of effect has been observed after multiple topical dosing as
Fig. 4. Changes in plasmacytoid dendritic cell (pDC ; A) and myeloid dendritic
cell (mDC ; B) frequency over12 wk of treatment. Plasmacytoid and myeloid
dendritic cell frequency, as a percent of peripheral bloodmononuclear cells in whole
blood, for the eight patients with cell marker data was displayed for treatment
cycle 1.
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compared with single dosing with resiquimod, a related mixed
TLR7/TLR8 analogue (29). One possibility for the lack of
observed efficacy, despite evidence of pharmacologic activity, is
that the activation signal induced by systemic 852A was too
generalized and decoupled from tumor antigen, or that this
signal just insufficient. It is conceivable that the increase in pre-
dose expression of activation markers on plasmacytoid den-
dritic cells over the treatment, which was observed in some
patients, may be the consequence of this generalized over-
activation.
Combining 852A with the depletion of regulatory T cells may
be an approach to enhance efficacy, as has been tried with other
immunotherapeutic modalities (30, 31). Nevertheless, the
major concern for lymphoablative chemotherapy, denileukin-
diftitox, or anti-CD25 antibody is still their specificity in
eliminating regulatory T cells (e.g., CD25 is also expressed on
activated CD4+ and CD8+ T cells, driving their expansion and
survival), which requires additional investigations to clarify
their effects on antitumor immunity (32). An alternative
strategy would be to block the molecules that mediate immune
suppression, such as CTLA-4, which has shown promising
objective response in melanoma when coadministered with
peptide vaccine (33). TLR activation seems to induce prolifer-
ation of regulatory T cells thereby enhancing their immuno-
suppressive activity. In addition to other TLRs, regulatory T cells
express TLR8 and adoptive transfer of TLR8 agonist–treated
regulatory T cells was surprisingly shown to enhance antitumor
activity in animals (34–36). Unfortunately, because TLR8 is
nonfunctional in rodent species except under special condi-
tions, exploring the individual contributions of TLR7 versus
TLR8 in animal tumor models may be difficult because TLR7,
TLR7/TLR8, and TLR8 agonists behave similarly (37).
Alternative dosing schedules might prove to be more
effective, if the dosing interval is too short to allow adequate
plasmacytoid dendritic cell recovery; TLR-induced plasmacytoid
dendritic cell maturation to a non–IFN-producing phenotype
or counterregulatory mechanisms may result in functional
plasmacytoid dendritic cell ‘‘exhaustion’’ (38–40). Combining
852A with other therapeutic modalities may also enhance
efficacy. Imiquimod combined with cyclophosphamide was
more effective than either alone in the murine MC-26 model
(41). Interleukin-2 combined with topical imiquimod cleared
cutaneous melanoma metastases refractory to imiquimod alone
(42). CpG, a TLR9 agonist that also induces plasmacytoid
dendritic cell IFN-a production, is being investigated in
combination with chemotherapy for metastatic melanoma.9
Combining topical imiquimod with photodynamic therapy
induced regression not only of treated cutaneous melanoma
metastasis but also of a distant metastasis (43). It can be
postulated that the physical destruction of the cells makes more
tumor antigens available, allowing imiquimod to more
effectively enhance tumor-specific cell-mediated immunity.
Thus, administration of 852A after radiation therapy of deep
solid tumors and its use as an adjuvant during immunization
with selected tumor antigens represent the alternatives to be
explored. Combining 852A with other therapies, of course, may
also result in enhance toxicity, especially with agents or
modalities that are causing flu-like syndrome, have hemato-
logic toxicities, or cause inflammation.
In conclusion, whereas objective clinical responses were not
observed, disease stabilization, adequate tolerance, and sys-
temic immune activation were observed with systemic admin-
istration of 852A in patients with advanced metastatic
melanoma. Future studies of 852A in melanoma will provide
more information on approaches (combination or adjunctive)
warranting highest efficacy.
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